SeaStar Medical (ICU) announced that it has successfully reached enrollment of 125 patients in the NEUTRALIZE-AKI pivotal clinical trial. Additionally, it has activated Methodist Hospital Metropolitan of San Antonio, Texas, as its 16th clinical trial site. The company also reported that it remains on track to receive results from the per protocol prespecified interim analysis of the first 100 patients in the trial in the third quarter of 2025. The analysis is being conducted by the trial’s independent Data Safety Monitoring Review Board, DSMB. The company intends to disclose to its stakeholders only the top-line decision from the analysis by the DSMB to preserve the integrity to the ongoing trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar Medical Faces Nasdaq Listing Deficiency Notice
- SeaStar Medical Announces Securities Purchase Agreement
- SeaStar Medical announces $4.4M registered direct offering priced at-the-market
- SeaStar Medical reports ‘positive’ results for QUELIMMUNE therapy in AKI
- SeaStar Medical Appoints New Board Chair Jennifer Baird